IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs

Core Insights - IDEAYA Biosciences is set to present three clinical stage pipeline programs at the AACR Annual Meeting, showcasing potential first-in-class therapies targeting various cancer types [1][2]. Group 1: Pipeline Programs - The three highlighted programs include IDE034, a bi-specific antibody-drug conjugate targeting PTK7 and B7H3; IDE574, a dual inhibitor of lysine acetyltransferases KAT6 and KAT7; and IDE892, a PRMT5 inhibitor [1][3]. - These programs are currently undergoing Phase 1 clinical studies to assess their safety, tolerability, pharmacokinetics, and efficacy across multiple solid tumor indications, including lung, colorectal, pancreatic, breast, and prostate cancers [1][3]. Group 2: Presentation Details - The poster presentations will cover the following topics: - IDE034's enhanced antitumor activity compared to mono-specific ADCs, scheduled for April 19, 2026 [3]. - IDE574's ability to disrupt tumor lineage identity and drug tolerance, scheduled for April 21, 2026 [3]. - IDE892's selective inhibition of PRMT5, also scheduled for April 21, 2026 [3]. Group 3: Company Overview - IDEAYA Biosciences focuses on precision medicine in oncology, aiming to develop transformative therapies through a combination of small-molecule drug discovery, structural biology, and bioinformatics [4]. - The company is committed to creating targeted therapies that align with the genetic drivers of cancer, emphasizing synthetic lethality and antibody-drug conjugates [4].